MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Read More…
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Phone972-8932-4010
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.40 million
Profitability
Miscellaneous
Employees73
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Mediwound (NASDAQ:MDWD) Frequently Asked Questions
What is Mediwound's stock symbol?
Mediwound trades on the NASDAQ under the ticker symbol "MDWD."
How were Mediwound's earnings last quarter?
Mediwound Ltd (NASDAQ:MDWD) released its earnings results on Tuesday, August, 13th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03. The biopharmaceutical company had revenue of $20.75 million for the quarter, compared to the consensus estimate of $7.03 million. Mediwound had a net margin of 70.54% and a negative return on equity of 156.56%. View Mediwound's Earnings History.
When is Mediwound's next earnings date?
What price target have analysts set for MDWD?
2 brokers have issued 1 year price objectives for Mediwound's shares. Their forecasts range from $5.50 to $7.00. On average, they anticipate Mediwound's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 121.6% from the stock's current price. View Analyst Price Targets for Mediwound.
What is the consensus analysts' recommendation for Mediwound?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mediwound.
What are Wall Street analysts saying about Mediwound stock?
Here are some recent quotes from research analysts about Mediwound stock:
- 1. According to Zacks Investment Research, "MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. " (10/15/2019)
- 2. HC Wainwright analysts commented, "We are initiating coverage of MDWD with 12- month price target of $5.50 per share. We derive our price target based on an NPV analysis of projected future revenues from 2030, assuming a 11% discount rate and a 0.5% terminal growth rate." (8/5/2019)
Has Mediwound been receiving favorable news coverage?
Headlines about MDWD stock have trended somewhat negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Mediwound earned a media sentiment score of -1.2 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Mediwound.
Are investors shorting Mediwound?
Mediwound saw a decline in short interest in the month of September. As of September 15th, there was short interest totalling 187,700 shares, a decline of 5.9% from the August 15th total of 199,500 shares. Based on an average daily volume of 58,100 shares, the days-to-cover ratio is presently 3.2 days. Currently, 1.2% of the company's shares are sold short. View Mediwound's Current Options Chain.
Who are some of Mediwound's key competitors?
Some companies that are related to Mediwound include Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), True Drinks (TRUU), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), FitLife Brands (FTLF), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Entia Biosciences (ERGO), Actelion (ALIOF), Beleave (BE), Beleave (BE) and Rock Creek Pharmaceuticals (RCPIQ).
What other stocks do shareholders of Mediwound own?
Who are Mediwound's key executives?
Mediwound's management team includes the folowing people:
- Mr. Gal Cohen, Pres & CEO (Age 46)
- Prof. Lior Rosenberg, Co-Founder & Chief Medical Technology Officer (Age 73)
- Mr. Sharon Malka CPA, MBA, Chief Financial & Operation Officer (Age 47)
- Mr. Carsten Henke, Chief Commercial Officer of Europe (Age 53)
- Dr. Ety Klinger, Chief R&D Officer (Age 57)
How do I buy shares of Mediwound?
Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Mediwound's stock price today?
One share of MDWD stock can currently be purchased for approximately $2.82.
How big of a company is Mediwound?
Mediwound has a market capitalization of $76.64 million and generates $3.40 million in revenue each year. The biopharmaceutical company earns $-1,060,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Mediwound employs 73 workers across the globe.View Additional Information About Mediwound.
What is Mediwound's official website?
How can I contact Mediwound?
Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]
MarketBeat Community Rating for Mediwound (NASDAQ MDWD)
MarketBeat's community ratings are surveys of what our community members think about Mediwound and other stocks. Vote "Outperform" if you believe MDWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
